These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30611667)

  • 1. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches.
    Pan Q; Fan JG
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):1-3. PubMed ID: 30611667
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.
    Polyzos SA; Kountouras J
    Ann Hepatol; 2020; 19(5):579-580. PubMed ID: 32702498
    [No Abstract]   [Full Text] [Related]  

  • 4. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Castera L
    Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
    Gunn NT; Shiffman ML
    Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
    Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease.
    Mandelia C; Kabbany MN; Conjeevaram Selvakumar PK; Alkhouri N
    Biomark Med; 2018 Mar; 12(3):265-273. PubMed ID: 29517271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.
    Baršić N; Lerotić I; Smirčić-Duvnjak L; Tomašić V; Duvnjak M
    World J Gastroenterol; 2012 Aug; 18(30):3945-54. PubMed ID: 22912545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.
    Rosso C; Caviglia GP; Abate ML; Vanni E; Mezzabotta L; Touscoz GA; Olivero A; Marengo A; Rizzetto M; Bugianesi E; Smedile A
    Dig Liver Dis; 2016 Jan; 48(1):55-61. PubMed ID: 26514735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperhomocysteinemia--a predictor of inflammatory changes in the liver].
    Zviagintseva TD; Hlushchenko SV
    Lik Sprava; 2014 Nov; (11):154-5. PubMed ID: 25528857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in nonalcoholic fatty liver disease.
    Neuman MG; Cohen LB; Nanau RM
    Can J Gastroenterol Hepatol; 2014 Dec; 28(11):607-18. PubMed ID: 25575111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.